cognitive functions and dementia · cognitive functions and dementia doc. mudr. jakub hort, phd....
TRANSCRIPT
Cognitive functions and dementia
Doc. MUDr. Jakub Hort, PhD. Dept. of Neurology, 2nd Medical
Faculty, Charles University and Motol Teaching Hospital
What is dementia?
• DE-MENTIA = „without mind“
• acquired memory dysfunction (= set of signs and symptoms) and other cognitive domains beyond normal aging
→ attention
→ language
→ executive functions (decision making)
• duration of at least 6 month (shorter = delirium)
2
Clinical manifestation of dementia
• Cognitive dysfunction memory, thinking and learning disturbances,
visuo-spatial impairment
executive functions impairment
failure of symbolic functions
3
• Behavioral disorders personality changes
emotional changes, depression and anxiety, hallucinations and delusions
irritatability, aggressiveness, apathy, sleep disturbances
• Limitation in everyday Activities homework
grooming, continence, walking
complex activities (employment, driving, etc.)
Dementia is about forgeting, but forget it!
4
Incidence of dementia - increases with age
6
Growdon, 2007
Pre
vale
nce
(%
(
age
New dementia cases per year in EU compared with other diseases
7
600,0001
575,0002
500,0003
350,0004
0
250,000
500,000
750,000
1,000,000
Dementia Stroke Diabetes Breast Cancer
An
nu
al In
cid
en
ce
1. Iliffe S, et al. Fam Pract. 2003;20:376-381. 2. European Stroke Initiative. Available at: http://www.eusi-stroke.com. 3. Wild S, et al. Diabetes Care. 2004;27:1047-1053. 4. Ferlay J, et al. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Lyon, France;
IARCPress, 2001.
Types of dementias
10
Parkinson's disease
Lewy body
Alzheimer's Disease
Vascular dementia
Mixed dementia
Frontotemporal
dementia
Frontotemporal dementia • 5-10%
• peak 45-65 years
• neuronal loss changes in frontal and temporal region → mutation of the tau protein
• Frontal variant → personality changes, behavioral dysfunctions, failure in executive functions
• Temporal variant → semantic dementia, speech impairment, (anomia), failure of understanding
11
Dementia with Lewy bodies
• 10-20%
• neuronal changes due to synucleopathy → brain stem, diencefalon, anterior cingulum, amygdala, cortex
→ fluctuating cognitive impairment
→ persistent visual halucinations
→ extrapyramidal symptoms
→ neuroleptic sensitivity
12
Vascular dementia • 10-15%
• heterogenous group → cognitive impairment due to vascular changes (ischemia, hemorhagy) with various clinical symptoms
• cortical dementia
• subcortical dementia
• posthemorhagical dementia
• hereditary dementia (CADASIL)
13
Alzheimer's Disease (AD)
15
• progressive neurological disease
• most common type of dementia
• risk factors
age
apolipoprotein E4 (APOE-4)
female
low education
family history of AD or Down syndrome
head trauma
cerebrovascular disease (hypertension)
diabetes, hyperhomocysteinemia, high fat level in diet
• protecting factors → antioxidants, NSA, hypolipidemics
How was it?
16
Alois Alzheimer (1864-1915) Oskar Fischer (1876 – 1942)
17
37 meeting of psychiatrists from south Germany in Tübingen, 1906 Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiat 1907;64:146-148 1. patient
Fischer O. Miliare nekrosen mit drusigen Wucherungen der Neurofibrillen, eine regelmässige Veränderung der Hirnrinde bei seniler Demenz. Monatssch Psychiat Neurol 1907;22:361-372 12 pacients
10 controls, 10 psychosis, 45 neurosyphilis
18
senile
plaques
neurofibrilary
tangles
19
Courtesy of doc. Bartos
20
ß-secretasis
g-secretasis
a-secretasis
21
Tau protein
22
Clinical course in AD
23
time
Imp
airm
en
t memory only
Clinical course in AD
24
time
Imp
airm
en
t memory +
attention
Clinical course in AD
25
time
Imp
airm
en
t memory +
aphasia
visuospatial
attention
Can we diagnose AD before the onset of dementia?
What are the early signs of the disease?
26
New diagnostic criteria for AD
• Memory impairment combined with
- typical findings in CSF (beta-amyloid, tau protein)
- MRI volumometry (hippocampal atrophy)
- perfusion on SPECT or metabolism on PET (hypoperfusion in temporoparietal and frontal brain regions)
27
Dubois et al, 2007, DSM V - 2011
MRI volumetry
29
HOŘÍNEK, Daniel, PETROVICKÝ, Pavel, HORT, Jakub et al. Amygdalar volume and psychiatric symptoms in Alzheimer´s disease: an MRI analysis, ACTA NEUROL SCANDINAVICA113, 2006, No.1., p. 40-45
HOŘÍNEK, Daniel , VARJASSYOVÁ, Alexandra and HORT, Jakub. Magnetic Resonance analysis of Amygdalar volume in Alzheimer's Disease. CURR OPIN PSYCHIATRY, 20, 2007, No. 3, p.273-277
30
Senzitivity 80-85% demented vs. non-demented
Specificity 76-80%
Kahle-Wrobleski et al., 2007
Screening tests in dementia
31
Mini Mental State Examination
32
MOCA sensitivity 90% specificity 90%
Nasreddine et al., 2005
Earlier and cheaper diagnosis?
33
EFNS guidelines 2010
34
AD – insidiously progressive disease
• Dementia syndrome in AD is preceded by amyloid deposition in the brain (1 decade earlier)
• 20%-30% of cognitively normal elderly persons have brain AD pathology
• 50%-70% of patients with MCI have AD pathology (conversion 15% per year)
35
Hansson O, et al. Lancet Neurol. 2006;5:228-234; Okello A, et al. Neurology. 2009;73:754-760 ; Jack CR Jr, et al. Lancet Neurol. 2010;9:119-128
Progression of neuropathology in AD (years)
36
A
NFT
Neurons/ synapses
prodromal MCI AD
Neurons/ synapses
NFT A
ageing
Normal ageing?
Preclinical AD?
MCI
prodromal AD
dementia
Who?
Earlier diagnostics
38
AD – management strategies
• normal ageing – (no symptoms), AD pathology not present
influencing risk factors +,-
• preclinical AD – (no symptom), AD pathology present
primary prevention
• prodromal AD ( MCI syndrome)
secondary prevention
• full blown AD (dementia syndrome)
treatment of established AD
39
Cholinesterase inhibitors
- acetylcholinesterasis (brain - neurotransmission) – donepezil, galantamin, rivastigmin
- butyrylcholinestrasis
(brain – inflamation, neurodegeneration) rivastigmin
internal organs
41
Acetyl CoA
Choline
ACh
ACh
Cholin acetyltransferasis
M2, M3 N - +
M1, M3 N
Ionotropic
M2, M4
cAMP
Presynaptic part
Postsynaptic part
ACh
ACh
AChE
DONEPEZIL
N = nicotinic ACh receptors M = muscarinic Ach receptors
ACh ACh
+
Cholin
+ acetate
GALANTAMIN
BuChE
GLIE
RIVASTIGMIN
GLIA
Cholinergic synapse
42
NMDA receptor
AMPA receptor
Glutamate
Magnesium
+ -
+ Na
- + Ca2+
Ca 2+
43
MMSE = 3-14. Reisberg et al. N Engl J Med. 2003;348:1333-1341.
week
decline
improvement
SIB
sco
re
Monotherapy - memantine
44
MMSE = 5-14. Tariot et al. JAMA. 2004;291:317-324.
Combined therapy memantine + IChE
45
SIB
sco
re
week
decline
improvement
Adherence to therapy – motivation seeing the
improvement • symptomatic (IAChE) - delayed decline
• disease modifying - slowing of the decline
47
Gauthier S. Brain Aging 2002;2:9–22
Ch
ange
fro
m b
asel
ine
untreated
Initial improvement - IAChE
disease modifying
symptomatic
What improvement is possible today?
• Rivastigmin patch
• Donepezil oro-tabs
• Memantine once daily
• Higher dose of inhibitors - donepezil 23 mg • Combination therapy ChEI + memantine
• Severe dementia – theory versus practice
• Avoid non-evidence based (nootropics)
48
Level A evidence for AD
no Level A evidence
Non-evidence based medications
49
Net cost of care per AD patient over 3 years
50
Fagnani et al., 2004
Conclusions
• forget dementia
• AD is insidiously progressive disease
• cholinesterase inhibitors, butyrylcholinesterasis • don't forget they will hardly ever disappear
• disease modifying therapies
• investment in treatment should go with investments in diagnostics
53